Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Lung Cancer

Free Subscription 13.04.2026 1 Ann Oncol 3 Ann Surg 1 Ann Thorac Surg 5 BMC Cancer 1 Br J Cancer 1 Cancer 2 Cancer Res 10 Clin Lung Cancer 1 Eur J Cardiothorac Surg 2 Int J Cancer 1 J Natl Cancer Inst 1 J Nucl Med 8 J Thorac Oncol 1 JAMA Oncol 1 Lung Cancer 1 Oncologist 5 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Oncol

1. FELIP E, Rojas CI, Schenker M, Kowalski DM, et al
   Corrigendum to "Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial": [Ann Oncol 36 (2025) 775-785].
   Ann Oncol. 2026 Apr 7:S0923-7534(26)00048-7. doi: 10.1016/j.annonc.2026.
   PubMed        
   
   

   
   Ann Surg

2. LANG-LAZDUNSKI L, Zhang YZ, Nicholson AG
   Multimodality Therapy Including Pleurectomy/Decortication in Pleural Mesothelioma: Long-term Outcomes in 152 Consecutive Patients: A Retrospective Cohort Study.
   Ann Surg. 2026;283:725-733.
   PubMed         Abstract available
   
   
3. PAAJANEN J, Richards WG, Xie Y, Mazzola E, et al
   Recurrence Patterns and Management after Pleurectomy Decortication for Pleural Mesothelioma.
   Ann Surg. 2026;283:734-742.
   PubMed         Abstract available
   
   
4. JOLISSAINT JS, Lobaugh SM, Goldman DA, McIntyre SM, et al
   Frequency and Natural History of Emergency General Surgery Conditions in Cancer Patients: A SEER-medicare Population Analysis.
   Ann Surg. 2026;283:783-790.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

5. POHLMAN A, Odeh B, Raad W, Lubawski J, et al
   Lobar versus Sub-lobar Lung Resection for Early-Stage Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer.
   Ann Thorac Surg. 2026 Mar 31:S0003-4975(26)00308.
   PubMed         Abstract available
   
   

   
   BMC Cancer

6. TAO Z, Li S, Xia H, Ni Z, et al
   Decoding anoikis-related genes in lung adenocarcinoma brainmetastasis via single-cell RNA sequencing: CD44-mediated functions.
   BMC Cancer. 2025;26:145.
   PubMed         Abstract available
   
   
7. TANG Y, Huang Y, Chen L, Huang Z, et al
   A preliminary study on the prognostic impact of platelet to monocyte ratio and its related genes on non-small cell lung cancer.
   BMC Cancer. 2026;26:451.
   PubMed         Abstract available
   
   
8. VAZQUEZ-QUIROGA S, Garcia-Martinez S, Jimenez-Meseguer M, Irusta-Gonzalo A, et al
   Evaluation of the exposure-response relationship of pembrolizumab in non-small cell lung cancer: observational study protocol in real-world clinical practice.
   BMC Cancer. 2026 Apr 7. doi: 10.1186/s12885-026-15976.
   PubMed        
   
   
9. MA J, Zhu S, Li X, Gao S, et al
   A novel diagnostic model combining ProGRP and inflammatory biomarkers for early detection of lung cancer: development and validation in treatment-naive cohorts.
   BMC Cancer. 2026 Apr 6. doi: 10.1186/s12885-026-15961.
   PubMed        
   
   
10. WEI T, Zhong G, Wang J, Huang C, et al
    Prognostic nutritional index improved the survival prediction of the revised Tokuhashi and Tomita scores for patients with lung cancer spinal metastases.
    BMC Cancer. 2026 Apr 7. doi: 10.1186/s12885-026-15952.
    PubMed        
    
    

    
    Br J Cancer

11. OZAWA Y, Yamamoto K, Sugawara S, Niho S, et al
    Impact of tumor location on the efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.
    Br J Cancer. 2026 Apr 9. doi: 10.1038/s41416-026-03406.
    PubMed         Abstract available
    
    

    
    Cancer

12. SUZUKI K, Miyazaki K, Asano N, Takahashi H, et al
    Treatment and outcomes of pulmonary mucosa-associated lymphoid tissue lymphoma: A multicenter analysis of 186 patients.
    Cancer. 2026;132:e70390.
    PubMed         Abstract available
    
    

    
    Cancer Res

13. XIE Q, Wang Y, Fernandez A, Lei Y, et al
    Adaptive Regulation of dNTP Homeostasis Confers Osimertinib Resistance in EGFR-Mutant Non-small Cell Lung Carcinoma.
    Cancer Res. 2026 Apr 6. doi: 10.1158/0008-5472.CAN-25-3237.
    PubMed         Abstract available
    
    
14. MAO C, Wu S, Rajacharya GH, Wang M, et al
    DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer.
    Cancer Res. 2026 Apr 8. doi: 10.1158/0008-5472.CAN-25-3728.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

15. SUDA K, Sakai K, Ito M, Oiki H, et al
    Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non-Small-Cell Lung Cancer with EGFR Mutation.
    Clin Lung Cancer. 2026 Mar 10:S1525-7304(26)00036.
    PubMed         Abstract available
    
    
16. ZAKHARIA A, Bodner W, Halmos B, Garg M, et al
    Impact of Consolidation Durvalumab on Local Control Following Chemoradiotherapy for Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2026 Mar 16:S1525-7304(26)00038.
    PubMed         Abstract available
    
    
17. MINCHOM A, Cho BC, Leighl NB, Johnson ML, et al
    Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA Study.
    Clin Lung Cancer. 2026;27:259-272.
    PubMed         Abstract available
    
    
18. SHI H, Zhu H, Tang L, Lu J, et al
    Efficacy and Safety of Firmonertinib Plus Anlotinib as First-Line Treatment for Advanced NSCLC With EGFR Mutations: A Single-Arm, Phase I/II Trial.
    Clin Lung Cancer. 2026;27:170-179.
    PubMed         Abstract available
    
    
19. GULDBRANDSEN KF, Bloch M, Skougaard K, Albrecht-Beste E, et al
    Diagnostic Accuracy of [(18)F]FDG PET/CT versus CT for NSCLC Surveillance: Secondary Analysis of a Randomized Clinical Trial.
    Clin Lung Cancer. 2026;27:180-189.
    PubMed         Abstract available
    
    
20. ALWATARI Y, Vierkant RA, Aizpuru MJ, Saddoughi SA, et al
    Impact of Pulmonary Resection Extent on Nodal Upstaging in Clinical Stage IA1-2 NSCLC: Real-World Evidence of Low Detection Rates with Sublobar Resections.
    Clin Lung Cancer. 2026;27:190-200.
    PubMed         Abstract available
    
    
21. TANVETYANON T, Chen DT, Gray JE
    Relationship between PD-L1 Expression and Outcomes of Salvage Treatment Following Durvalumab Consolidation.
    Clin Lung Cancer. 2026;27:135-143.
    PubMed         Abstract available
    
    
22. SOYLER Y, Ozturk A, Uzel Sener M, Ozturk Ergur F, et al
    Diagnostic Performance of Tumor-to-Lymph Node SUV(max) Ratio in PET/CT-Guided EBUS-TBNA for NSCLC.
    Clin Lung Cancer. 2026;27:76-87.
    PubMed         Abstract available
    
    
23. TAO WT, Huang TW, Hsu HH, Chiang SW, et al
    The Impact of CT Attenuation on Subsolid Pulmonary Nodule Detection With the Zero Echo Time MRI Technique.
    Clin Lung Cancer. 2026;27:88-97.
    PubMed         Abstract available
    
    
24. KIM M, Youk J, Kim TM, Lee GW, et al
    A Phase II Study of Durvalumab, Doxorubicin, and Ifosfamide in Recurrent and/or Metastatic Pulmonary Sarcomatoid Carcinoma (KCSG LU-19-24).
    Clin Lung Cancer. 2026;27:58-64.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

25. VON MEYENFELDT EM, van Oyen D, van den Berg R, van Nassau F, et al
    Higher Enhanced Recovery Adherence is Associated With Shorter Length of Stay and Fewer Complications After Lung Resection.
    Eur J Cardiothorac Surg. 2026;68:ezag111.
    PubMed         Abstract available
    
    

    
    Int J Cancer

26. WANG J, Song P, Ge Y, Yang H, et al
    Effect of Interval Between Neoadjuvant Immunochemotherapy and Radical Resection of Non-Small Cell Lung Cancer: A Multicenter, Retrospective Cohort Study.
    Int J Cancer. 2026 Apr 9. doi: 10.1002/ijc.70473.
    PubMed         Abstract available
    
    
27. KOTO R, Yamamoto A, Takashima I, Iwao C, et al
    Survival by Detection Pathway in Patients With Lung Cancer-A Nationwide Descriptive Epidemiological Study in Japan.
    Int J Cancer. 2026 Apr 8. doi: 10.1002/ijc.70474.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

28. ROSHANI S, Boekel NB, Van Leeuwen FE, Rademakers SE, et al
    Predicting long-term absolute risk of lung cancer in Hodgkin lymphoma patients.
    J Natl Cancer Inst. 2026 Mar 23:djag090. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

29. AURIAC J, Lemoudda G, Hovhannisyan-Baghdasarian N, Pires M, et al
    Brain Metabolic Activity Measured by [(18)F]FDG PET/CT Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer.
    J Nucl Med. 2026 Apr 9:jnumed.125.271400. doi: 10.2967/jnumed.125.271400.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

30. PHAM R, Garama D, Malhotra A, Kwok A, et al
    Brief Report: Alectinib With Salvage Platinum-Taxane Chemotherapy in a Pregnant Woman With ALK-Rearranged NSCLC and Rapid Disease Progression Followed by a Successful Pregnancy.
    J Thorac Oncol. 2026;21:103522.
    PubMed         Abstract available
    
    
31. SEVERSON DT, Freyaldenhoven S, Wadowski B, Hung YP, et al
    Multiomic, Histologic, and scRNA-seq Profiling of Pleural Mesothelioma Reveals Negative Prognosis Associated With a Novel Uncommitted Molecular Phenotype.
    J Thorac Oncol. 2026;21:103529.
    PubMed         Abstract available
    
    
32. BURNS TF, Ammakkanavar NR, Hollebecque A, Lee DH, et al
    Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.
    J Thorac Oncol. 2026;21:103528.
    PubMed         Abstract available
    
    
33. ORTIZ-CUARAN S, Dupriez L, Nicq C, Lindsay CR, et al
    Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC.
    J Thorac Oncol. 2026;21:103531.
    PubMed         Abstract available
    
    
34. MCMAHON RA, Lee Min Chua K, Faivre-Finn C, Filippi AR, et al
    Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee.
    J Thorac Oncol. 2026 Apr 3:103643. doi: 10.1016/j.jtho.2026.103643.
    PubMed         Abstract available
    
    
35. LU S, Fang J, Yu Y, Fan Y, et al
    SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China.
    J Thorac Oncol. 2026 Apr 6:103713. doi: 10.1016/j.jtho.2026.103713.
    PubMed         Abstract available
    
    
36. SALAMA JK, Mix MD, Faivre-Finn C, Bezjak A, et al
    The Optimization of Radiotherapy in Lung Cancer Treatment: 20 Years of Progress.
    J Thorac Oncol. 2026;21:103578.
    PubMed         Abstract available
    
    
37. PUJOL JL, Milleron B, Bommart S
    Screening Lung Cancer in Population-Based Real-World Programs: Searching for Efficiency Indicators.
    J Thorac Oncol. 2026;21:103539.
    PubMed        
    
    

    
    JAMA Oncol

38. ROUSSEAU A, Foulon S, Planchard D, Remon J, et al
    Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab.
    JAMA Oncol. 2026 Apr 9. doi: 10.1001/jamaoncol.2026.0669.
    PubMed         Abstract available
    
    

    
    Lung Cancer

39. KANDEMIR EA, Roeper J, Ansmann L, Hiltermann TJN, et al
    Multidisciplinary tumor boards (MTBs) and survival Outcomes: Adherence to MTB recommendations in patients with lung cancer treated at two European cancer centers (AdThera-2).
    Lung Cancer. 2026;216:109403.
    PubMed         Abstract available
    
    

    
    Oncologist

40. GUZEL HG, Kivrak Salim D, Kilickap S, Kemal Y, et al
    Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis.
    Oncologist. 2026;31:oyag092.
    PubMed         Abstract available
    
    

    
    PLoS One

41. SIAHMANSUR TJ
    Comparison of the effects of different types of treatment protocols on the median and overall survival rates of non-small cell lung cancer patients: A real-world retrospective study.
    PLoS One. 2026;21:e0344658.
    PubMed         Abstract available
    
    
42. AKINYEMI O, Fasokun M, Eze A, Ugochukwu N, et al
    Association of medicaid expansion with lung cancer-specific and overall mortality: A difference-in-differences analysis.
    PLoS One. 2026;21:e0332292.
    PubMed         Abstract available
    
    
43. SHENG A, Yan C, Ye Y, Yang Z, et al
    The correlation between the pathological characteristics of pulmonary invasive mucinous adenocarcinoma and radiomic features and abnormal expression of the FoxM1 and Sox9 genes.
    PLoS One. 2026;21:e0345780.
    PubMed         Abstract available
    
    
44. 
    Retraction: Optimizing chemotherapeutic targets in non-small cell lung cancer with transfer learning for precision medicine.
    PLoS One. 2026;21:e0345987.
    PubMed        
    
    
45. LI Q, Zhang J, Meng S, Tian F, et al
    Correction: Correlation between self-regulatory fatigue and physical activity in lung cancer patients undergoing comprehensive treatment.
    PLoS One. 2026;21:e0346781.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum